Abstract Library

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#4075 A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors

Introduction: Data suggest that combined inhibition of VEGF and FGF is an effective antiangiogenic strategy and that concomitant inhibition of the mTOR pathway may be further synergistic.

Conference:

Presenting Author: Dasari A

Authors: Dasari A, Qiao W, Halperin D, Stanietzky N, Surabhi V,

Keywords: Extrapancreatic NET, Lenvatinib, Everolimus, Phase II,

#3795 Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors – A pooled analysis of five clinical trials

Introduction: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in systemic oncological therapies is still unknown, and there is a lack of evidence, especially in uncommon neoplasms like neuroendocrine tumors (NET).

Conference:

Presenting Author:

Authors: Hernando Cubero J, Roca-Herrera M, Garcia Alvarez A, Raymond E, Kulke M,

Keywords: Sex, Toxicity, Tyrosine Kinase Inhibitor,

#3729 Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors

Introduction: Immune checkpoint inhibitors have not been shown to be active in well-differentiated NETs, with response rates

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Al-Toubah T, Morse B, Haider M, Valone T,

Keywords: pembrolizumab, lenvatinib, neuroendocrine tumor, immunotherapy,

#3533 Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

Introduction: TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date.

Conference:

Presenting Author: Garcia-Alvarez A

Authors: Garcia Alvarez A, Hernando J, Jimenez-Valero G, Martinez A, Fazio N,

Keywords: Lenvatinib, Angiogenesis, Ang2, VEGFR2,